![]() Flotufolastat F-18 gallium | |
Clinical data | |
---|---|
Trade names | Posluma |
Other names | 18F-rhPSMA-7.3 |
License data | |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C63H9918FN12O25Si |
Molar mass | 1537.3 g·mol−1 |
3D model (JSmol) | |
| |
|
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.[1] The active ingredient is flotufolastat F-18 gallium.[1]
Flotufolastat F-18 was approved for medical use in the United States in May 2023.[1][2]
Medical uses
[edit]Flotufolastat F-18 is indicated for positron emission tomography of prostate-specific membrane antigen positive lesions in men with prostate cancer.[1][3]
References
[edit]- ^ a b c d e "Posluma- flotufolastat f-18 injection". DailyMed. 2 June 2023. Retrieved 25 June 2023.
- ^ "U.S. FDA Approves Blue Earth Diagnostics' Posluma (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer" (Press release). Blue Earth Therapeutics. 30 May 2023. Retrieved 25 June 2023 – via Business Wire.
- ^ Heo YA (September 2023). "Flotufolastat F 18: Diagnostic First Approval". Molecular Diagnosis & Therapy. 27 (5): 631–636. doi:10.1007/s40291-023-00665-y. PMID 37439946. S2CID 259843992.
External links
[edit]- Clinical trial number NCT04186819 for "Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)" at ClinicalTrials.gov
- Clinical trial number NCT04186845 for "Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)" at ClinicalTrials.gov